Biocon still bullish on oral insulin despite clinical trial disappointment
This article was originally published in Scrip
Executive Summary
Biocon, India's largest biotechnology company by revenue, has said that its oral insulin candidate IN-105 failed to meet the primary endpoint of a clinical study in India, although it continues to be upbeat about taking the drug forward via a partnership.